CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 134 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 1.59 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $20,337 | +36.2% | 1,364 | 0.0% | 0.01% | +57.1% |
Q2 2023 | $14,936 | +25.6% | 1,364 | 0.0% | 0.01% | +16.7% |
Q1 2023 | $11,894 | +36.4% | 1,364 | -1.9% | 0.01% | +20.0% |
Q4 2022 | $8,722 | +74.4% | 1,391 | -6.5% | 0.01% | +66.7% |
Q3 2022 | $5,000 | +25.0% | 1,487 | 0.0% | 0.00% | +50.0% |
Q2 2022 | $4,000 | +100.0% | 1,487 | +104.5% | 0.00% | +100.0% |
Q4 2021 | $2,000 | -33.3% | 727 | 0.0% | 0.00% | -50.0% |
Q3 2021 | $3,000 | 0.0% | 727 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $3,000 | 0.0% | 727 | 0.0% | 0.00% | 0.0% |
Q1 2021 | $3,000 | +200.0% | 727 | +127.9% | 0.00% | +100.0% |
Q4 2020 | $1,000 | 0.0% | 319 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $1,000 | -66.7% | 319 | -42.8% | 0.00% | -50.0% |
Q3 2019 | $3,000 | -25.0% | 558 | -10.3% | 0.00% | -33.3% |
Q2 2019 | $4,000 | -50.0% | 622 | 0.0% | 0.00% | -50.0% |
Q1 2019 | $8,000 | +14.3% | 622 | -2.5% | 0.01% | +100.0% |
Q3 2018 | $7,000 | – | 638 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |